Related Experiment Video
Updated: Feb 2, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Multiple Myeloma of the Young - a Single Center Experience Highlights Future Directions
Ildikó Pál1, Árpád Illés1, László Váróczy2
1Department of Hematology, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, Debrecen, H-4032, Hungary.
Abstract:
Multiple myeloma is quite uncommon in the young population. We performed a retrospective review in our database from 2006 to 2015 to examine the clinical features, outcomes and survival of multiple myeloma patients ≤40 years old. Among 312 newly diagnosed patients we found sixteen (5.1%) who were 40 years old or younger. Their characteristics including M-protein type, genetical alterations, clinical symptoms and disease stage were as various as those in the older population. All but two young patients underwent autologous stem cell transplantation after the induction treatment. Their response to treatment did not differ markedly from the older patients. We also compared the survival data of patiens ≤40 years and > 40 years old. The 5-year progression-free survival were 48% and 35%, the 5-year overall survival were 83% and 53% respectively, the latter showing a significant advantage for the younger population. 70% of the young patients received maintenance or consolidation therapy after the initial treatment. Although several effective new therapies have been introduced recently, there is still an unmet need for curative treatment options for young and fit multiple myeloma patients.
Insights
Multiple myeloma is rare in young adults. This study found that young patients (≤40 years) had similar treatment responses but significantly better survival rates compared to older patients.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Multiple myeloma is uncommon in individuals younger than 40 years.
- Understanding the characteristics and outcomes of young multiple myeloma patients is crucial.
Purpose of the Study:
- To investigate the clinical features, treatment outcomes, and survival rates of multiple myeloma patients aged 40 years or younger.
- To compare the outcomes of young multiple myeloma patients with those of older patients.
Main Methods:
- Retrospective review of a database from 2006 to 2015.
- Analysis of clinical data for 312 newly diagnosed multiple myeloma patients, focusing on a subgroup of 16 patients aged ≤40 years.
- Comparison of survival data between young (≤40 years) and older (>40 years) patient groups.
Main Results:
- Sixteen patients (5.1%) were diagnosed with multiple myeloma at age ≤40 years.
- Young patients exhibited diverse clinical characteristics, similar to older populations.
- Autologous stem cell transplantation was common in young patients, with comparable treatment responses to older patients.
- Young patients demonstrated significantly better 5-year progression-free survival (48% vs. 35%) and overall survival (83% vs. 53%) compared to older patients.
Conclusions:
- Younger multiple myeloma patients (≤40 years) experience superior survival outcomes compared to older counterparts.
- Despite advancements, there remains a need for curative treatment strategies for young, fit multiple myeloma patients.
Related Concept Videos
Molecules with Multiple Chiral Centers
Lattice Centering and Coordination Number
Types of Unit Cells
Imagine taking a large number of identical...
Bioavailability Study Design: Single Versus Multiple Dose Studies
Center of Gravity
Center of Gravity
To determine its location, the principle of moments can be utilized by dividing the object into...
Center of Mass
The knowledge of the center of mass can also help us to describe and predict the motion of objects. For example, when a ball is thrown...

